期刊
ACS NANO
卷 6, 期 3, 页码 2497-2505出版社
AMER CHEMICAL SOC
DOI: 10.1021/nn204885f
关键词
targeted drug delivery; cancer; nanovectors; hydrophilic carbon clusters; cetuximab; EGFR
类别
资金
- University of Texas Health Science Center, Houston (Department of Defense) [W8XWH-07-2-0101]
- Mission Connect Mild Traumatic Brain Injury Consortium
- Department of Defense [W81XWH-08-2-0143]
- Nanoscale Science and Engineering Initiative of the National Science Foundation under NSF through the NSF Center for Biological and Environmental Nanotechnology [EEC-0647452]
- University of Texas M.D. Anderson Cancer Center (UTMDACC)
- NIH Cancer Center [CA16672]
- UTMDACC Cancer Center [CA016672]
Current chemotherapeutics are characterized by efficient tumor cell-killing and severe side effects mostly derived from off-target toxicity. Hence targeted delivery of these drugs to tumor cells is actively sought. In an in vitro system, we previously demonstrated that targeted drug delivery to cancer cells overexpressing epidermal growth factor receptor (EGFR+) can be achieved by poly(ethylene glycol)-functionalized carbon nanovectors simply mixed with a drug, paclitaxel, and an antibody that binds to the epidermal growth factor receptor, cetuximab. This construct is unusual in that all three components are assembled through noncovalent interactions. Here we show that this same construct is effective in vivo, enhancing radiotherapy of EGFR+ tumors. This targeted nanovector system has the potential to be a new therapy for head and neck squamous cell carcinomas, deserving of further preclinical development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据